F
Francis S. Willard
Researcher at Eli Lilly and Company
Publications - 97
Citations - 5904
Francis S. Willard is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Heterotrimeric G protein & G protein-coupled receptor. The author has an hindex of 39, co-authored 93 publications receiving 5249 citations. Previous affiliations of Francis S. Willard include University of North Carolina at Chapel Hill & Australian National University.
Papers
More filters
Journal ArticleDOI
Structure of Gαi1 Bound to a GDP-Selective Peptide Provides Insight into Guanine Nucleotide Exchange
Christopher A. Johnston,Francis S. Willard,Mark R. Jezyk,Zoey Fredericks,Erik T. Bodor,Miller B. Jones,Rainer Blaesius,Val J. Watts,T. Kendall Harden,John Sondek,J. Kevin Ramer,David P. Siderovski +11 more
TL;DR: A GDP-selective Galpha binding peptide, KB-752, is reported that enhances spontaneous nucleotide exchange of Galpha(i) subunits and cast light onto a potential mechanism by which Galpha subunits adopt a conformation suitable forucleotide exchange.
Journal ArticleDOI
Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor‐mediated differentiation
Melinda D. Willard,Francis S. Willard,Xiaoyan Li,Steven D. Cappell,William D. Snider,David P. Siderovski +5 more
TL;DR: It is shown that RGS12 associates with the nerve growth factor (NGF) receptor tyrosine kinase TrkA, activated H‐Ras, B‐Raf, and MEK2 and facilitates their coordinated signaling to prolonged ERK activation, suggesting a critical role in coordinating Ras‐dependent signals that are required for promoting and/or maintaining neuronal differentiation.
Journal ArticleDOI
Allosteric modulation of endogenous metabolites as an avenue for drug discovery
Denise Wootten,Emilia Elizabeth Savage,Celine Valant,Lauren T. May,Kyle W. Sloop,James Ficorilli,Aaron D. Showalter,Francis S. Willard,Arthur Christopoulos,Patrick M. Sexton +9 more
TL;DR: It is demonstrated that allosteric ligands can cause marked potentiation of previously “inert” metabolic products of neurotransmitters and peptide hormones, a novel consequence of the phenomenon of probe dependence.
Journal ArticleDOI
Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
Francis S. Willard,Kyle W. Sloop +1 more
TL;DR: The glucagon-like peptide-1 (GLP-1) receptor is one of the best validated therapeutic targets for the treatment of type 2 diabetes mellitus (T2DM).
Journal ArticleDOI
Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor
TL;DR: A comprehensive review of currently disclosed small molecule GLP-1 receptor ligands is presented and examples of “ligand bias” and “probe dependency” for the GLP -1 receptor are discussed; these emerging concepts may influence further optimization of known molecules.